AngioDynamics/$ANGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AngioDynamics
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Ticker
$ANGO
Sector
Primary listing
Employees
675
Headquarters
Website
AngioDynamics Metrics
BasicAdvanced
$463M
-
-$0.78
0.78
-
Price and volume
Market cap
$463M
Beta
0.78
52-week high
$13.50
52-week low
$5.83
Average daily volume
519K
Financial strength
Current ratio
2.294
Quick ratio
1.192
Interest coverage (TTM)
-5,769.00%
Profitability
EBITDA (TTM)
-1.441
Gross margin (TTM)
54.15%
Net profit margin (TTM)
-10.67%
Operating margin (TTM)
-7.67%
Effective tax rate (TTM)
0.33%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-5.16%
Return on equity (TTM)
-17.10%
Valuation
Price to revenue (TTM)
1.535
Price to book
2.59
Price to tangible book (TTM)
4.2
Price to free cash flow (TTM)
-26.211
Free cash flow yield (TTM)
-3.82%
Free cash flow per share (TTM)
-0.43
Growth
Revenue change (TTM)
2.73%
Earnings per share change (TTM)
-86.99%
3-year revenue growth (CAGR)
-2.13%
10-year revenue growth (CAGR)
-1.47%
3-year earnings per share growth (CAGR)
-2.00%
10-year earnings per share growth (CAGR)
19.74%
What the Analysts think about AngioDynamics
Analyst ratings (Buy, Hold, Sell) for AngioDynamics stock.
Bulls say / Bears say
The Med Tech segment’s robust 22% year-over-year growth to $35.8 million in Q4 FY25 drove a 12.7% increase in overall revenue, underscoring the success of flagship products like Auryon and the thrombus management platform. (Investing.com)
AngioDynamics achieved full-year pro forma adjusted EBITDA of $7.6 million in FY25, turning profitable from a $3.2 million adjusted EBITDA loss in FY24, reflecting improved operating leverage and expense management. (Investing.com)
Management raised fiscal 2026 net sales guidance to $305–310 million with expectations of positive free cash flow and continued Med Tech expansion, signaling confidence in its growth trajectory. (Investing.com)
Despite improvements, AngioDynamics reported a GAAP net loss of $34.0 million, or $0.83 per share, in FY25, highlighting persistent unprofitability. (AngioDynamics)
The traditional Med Device segment delivered only 0.8% pro forma sales growth to $166.0 million in FY25, lagging the higher-growth Med Tech business and pointing to limited diversification benefits. (AngioDynamics)
Ongoing tariff headwinds are expected to negatively impact gross margins by approximately 1.5 percentage points and adjusted EBITDA by up to $4.5 million in FY26, posing a risk to profitability. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
AngioDynamics Financial Performance
Revenues and expenses
AngioDynamics Earnings Performance
Company profitability
AngioDynamics News
AllArticlesVideos
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
Business Wire5 days ago
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
Business Wire3 weeks ago
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AngioDynamics stock?
AngioDynamics (ANGO) has a market cap of $463M as of October 07, 2025.
What is the P/E ratio for AngioDynamics stock?
The price to earnings (P/E) ratio for AngioDynamics (ANGO) stock is 0 as of October 07, 2025.
Does AngioDynamics stock pay dividends?
No, AngioDynamics (ANGO) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next AngioDynamics dividend payment date?
AngioDynamics (ANGO) stock does not pay dividends to its shareholders.
What is the beta indicator for AngioDynamics?
AngioDynamics (ANGO) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.